These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 23693095

  • 21. Targeting mTOR/p70S6K/glycolysis signaling pathway restores glucocorticoid sensitivity to 4E-BP1 null Burkitt Lymphoma.
    Gu L, Xie L, Zuo C, Ma Z, Zhang Y, Zhu Y, Gao J.
    BMC Cancer; 2015 Jul 20; 15():529. PubMed ID: 26189041
    [Abstract] [Full Text] [Related]

  • 22. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B, Chaire V, Lucchesi C, Karanian M, Pineau R, Laroche-Clary A, Italiano A.
    Oncotarget; 2017 Jan 31; 8(5):7878-7890. PubMed ID: 28002802
    [Abstract] [Full Text] [Related]

  • 23. PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas.
    Chen D, Mao C, Zhou Y, Su Y, Liu S, Qi WQ.
    Int J Oncol; 2016 Jan 31; 48(1):253-60. PubMed ID: 26549638
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
    Subbiah V, Brown RE, McGuire MF, Buryanek J, Janku F, Younes A, Hong D.
    Oncotarget; 2014 Jan 15; 5(1):95-102. PubMed ID: 24395633
    [Abstract] [Full Text] [Related]

  • 33. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
    Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH, Guha A.
    Int J Cancer; 2010 Jan 15; 126(2):563-71. PubMed ID: 19634141
    [Abstract] [Full Text] [Related]

  • 34. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT, Yang KX, Yu J, Cao YY, Ren JS, Hao JJ, Pan BQ, Ma S, Yang LY, Cai Y, Wang MR, Zhang Y.
    J Mol Med (Berl); 2018 Aug 15; 96(8):807-817. PubMed ID: 29959473
    [Abstract] [Full Text] [Related]

  • 35. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
    Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L.
    Oncotarget; 2016 Nov 08; 7(45):72886-72897. PubMed ID: 27662658
    [Abstract] [Full Text] [Related]

  • 36. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.
    Mol Cancer; 2012 Nov 20; 11():85. PubMed ID: 23167739
    [Abstract] [Full Text] [Related]

  • 37. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
    Li J, Wang X, Xie Y, Ying Z, Liu W, Ping L, Zhang C, Pan Z, Ding N, Song Y, Zhu J.
    Int J Cancer; 2018 Jan 01; 142(1):202-213. PubMed ID: 28905990
    [Abstract] [Full Text] [Related]

  • 38. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
    Jin Z, Qing K, Ouyang Y, Liu Z, Wang W, Li X, Xu Z, Li J.
    J Exp Clin Cancer Res; 2016 Mar 24; 35():52. PubMed ID: 27009084
    [Abstract] [Full Text] [Related]

  • 39. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR, Al-Romaizan M, Ahmed M, Thangavel S, Al-Dayel F, Beg S, Uddin S, Siraj AK, Al-Kuraya KS.
    Mol Med; 2015 May 26; 21(1):466-78. PubMed ID: 26023849
    [Abstract] [Full Text] [Related]

  • 40. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S, Vander Broek R, Shah S, Eytan DF, Pierce ML, Carlson SG, Coupar JF, Zhang J, Cheng H, Chen Z, Van Waes C.
    Clin Cancer Res; 2015 Sep 01; 21(17):3946-56. PubMed ID: 25977343
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.